Anondita MedicareShare price, financial results, shareholding and management
- Market cap
- ₹1,978 cr
- Stock P/E
- 57.7peers 15.1
- Book value
- ₹67.9
- Price to book
- 15.29
- EV / operating profit
- 39.5
- Market cap to sales
- 14.39
- ROCE · FY26
- 44.5%
- ROE · FY26
- 41.3%
- ROE, 3-year average
- 41.3%
- Operating margin · FY26
- 36.9%peers 14.0%
- Sales growth, 3 years
- +78.5%
- Profit growth, 3 years
- +114.4%
- Debt to equity
- 0.26peers 0.14
- Borrowings
- ₹33.6 cr
- Interest cover
- 14.2×
- Cash from business / op. profit
- 21%
- Debtor days
- 138
- Pledged
- 0.00%
- Promoter holding
- 59.26%
- Change in promoter holding
- -3.14 pts
- Shareholders
- 2,070
- 52-week high / low
- ₹1,316 / ₹602
- Dividend yield
- 0.00%
- Face value
- ₹10
Tap or hover on any figure for what it means. Our arithmetic on reported figures, at the latest close.
Anondita Medicare share price chart
Close on 19 Nov 2026 · -1.97% on the day · Vol 17,100
Daily prices to 19 Nov 2026, adjusted for splits and bonuses. Closing prices only: check the exchange for the live price.
Share price returns
To the close of 19 Nov 2026
- 1 month
- +3.1%
- 3 months
- -3.4%
- 6 months
- -2.6%
- 1 year
- +60.4%
- Since IPO
- +616.2%
- Traded a day, 20 days
- ₹5.33 cr
- Taken for delivery
- 70%
Business growth
Sales and net profit, from the reported results
| Sales | Profit | |
|---|---|---|
| FY26 on FY25 | +78% | +114% |
| 3 years, a year | - | - |
| Latest half, H2 FY26 | +81% | +113% |
About Anondita Medicare: business, products and customers
Anondita Medicare makes condoms at its own plant in Noida and sells them under its own brand, Cobra, to shops in several states and to government health programmes. Its shares trade on NSE Emerge.
Anondita Medicare makes male condoms at its plant in Noida, Uttar Pradesh, and sells them under its own brand, COBRA, in flavours such as strawberry, mint, chocolate and coffee. Every condom is tested electronically, and the company prints and packs in house. It also supplies condoms to government buyers such as the Central Medical Services Society for the family planning programme.
The business began in 1999 as a proprietorship of Anupam Ghosh that packed and sold condoms and gloves; it started making condoms in 2004 and for years made them for other brands, including Mankind Pharma's Manforce. The company was formed in March 2024 to take over that business and bought the subsidiary Anondita Healthcare and Rubber Products India Limited, which sells COBRA products along with gloves, pregnancy test kits and other wellness items. The shares listed on NSE Emerge on 1 September 2025.
Read more about the business
Revenue from operations was ₹137.4 cr in FY26; the chief financial officer said on the May 2026 call that about ₹118 cr came from condoms and about ₹19 cr from gloves, and that about 42% of sales went to government buyers. The chief financial officer also said government payments take at least 120 days, and trade receivables stood at ₹51.9 cr at March 2026.
Capacity rose to 869 million pieces a year after 307 million pieces were added on 23 February 2026, and more lines are on trial or being built. The company reports trial production of female condoms in latex and non latex, MDSAP and SABS certificates for selling abroad, and trial export orders from a partner in Kenya.
From the offer document, the 2025-26 annual report, the June 2026 investor presentation and the May 2026 earnings call.
Read the deeper study ↓In its favour
- Sales have grown very fast: 78% a year last year.
- It earns a high return on the money it uses: ROCE 45% in FY26.
- It has little debt for its size: debt to equity 0.26.
To watch
- Four new lines on trial and four more being built, due by January 2027 (Annual report 2025-26, p.13).
- The South African government supply: approved for five years, with the purchase order still pending at the May 2026 call (Earnings call transcript, May 2026, p.8).
- Supply under the Central Medical Services Society family planning tender for 8,00,62,000 condoms, where the company was declared L1 in August 2026 (Press release, September 2026, p.2).
- UN qualification for exports, still pending at the May 2026 call (Earnings call transcript, May 2026, p.9).
- The promoters' share has come down: 59.26%, from 61.79%.
From the company's documents first, then the reported figures read by fixed rules, the same for every company. Facts, not a view on the shares.
Anondita Medicare revenue and profit growth
Half-yearly results · Profit and lossSales have grown very fast. Last year profit grew faster than sales, so the company kept more from each rupee of sales.
SME companies report every six months. In the latest half, sales were higher than in the same half a year before. Profit grew faster than sales.
Anondita Medicare half-yearly results
SME companies report every six months · ₹ crore
| H1FY25 | H2FY25 | H1FY26 | H2FY26 | |
|---|---|---|---|---|
| Sales | 31 | 46 | 54.10 | 83.32 |
| Expenses | 22 | 30 | 34.90 | 51.85 |
| Operating profit | 10 | 16 | 19.20 | 31.46 |
| OPM | 31.0% | 35.0% | 35.5% | 37.8% |
| Interest | 1 | 1 | 1.82 | 1.71 |
| Depreciation | 0 | 0 | 0.41 | 0.67 |
| Profit before tax | 8 | 14 | 17.38 | 29.51 |
| Net profit | 6 | 10 | 13.02 | 21.28 |
Anondita Medicare profit and loss
Full years to March, FY25 to FY26 · ₹ crore, consolidated where reported
| FY25 | FY26 | |
|---|---|---|
| Sales | 77 | 137.42 |
| Expenses | 51 | 86.75 |
| Operating profit | 26 | 50.67 |
| OPM | 33.0% | 36.9% |
| Other income | 0 | 0.84 |
| Interest | 3 | 3.54 |
| Depreciation | 1 | 1.08 |
| Profit before tax | 22 | 46.89 |
| Tax rate | 27.3% | 26.9% |
| Net profit | 16 | 34.30 |
| EPS ₹ | 11.34 | 21.30 |
| Dividend payout | 0.0% | 0.0% |
The years to FY25 come rounded to the nearest crore in the source.
Anondita Medicare profitability
Margins and returns on capitalLast year the company kept more from each rupee of sales than the year before. It earns a high return on the money it uses.
Operating margin, every year
Per cent of sales kept before interest, depreciation and tax
| FY25 | FY26 | |
|---|---|---|
| Operating margin | 33.0% | 36.9% |
| Tax rate | 27.3% | 26.9% |
| ROCE | · | 44.5% |
| ROE | · | 41.3% |
| Dividend payout | 0.0% | 0.0% |
Anondita Medicare debt and cash flow
Balance sheet · Cash flow · Working capitalThe company's own money, its net worth, has grown fast. Its loans are smaller than its own money. Last year the business brought in less cash than it showed as profit, so part of the profit is still to be collected. It spent more on assets and investments than the business brought in, and raised the rest from loans or shares. Customers take about as long to pay as they did in FY25.
Bars below the line are cash going out.
Anondita Medicare balance sheet
At each 31 March · ₹ crore
| FY25 | FY26 | |
|---|---|---|
| Equity capital | 13 | 18.09 |
| Reserves | 24 | 111.15 |
| Net worth | 37 | 129.24 |
| Borrowings | 27 | 33.60 |
| Other liabilities | 13 | 21.99 |
| Total liabilities | 77 | 184.83 |
| Fixed assets | 13 | 39.29 |
| Capital work in progress | 6 | 42 |
| Investments | 3 | 3.31 |
| Other assets | 55 | 100.23 |
| Receivables | · | 51.86 |
| Inventory | · | 20.75 |
| Cash | · | 9.65 |
| Trade payables | · | 8.03 |
Anondita Medicare cash flow
₹ crore
| FY25 | FY26 | |
|---|---|---|
| Cash from operations | -7 | 10.64 |
| Cash from investing | -19 | -62.70 |
| Cash from financing | 26 | 61.28 |
| Net cash flow | 0 | 9.22 |
| Capital spending | · | 62.81 |
Working capital
Days
| FY25 | FY26 | |
|---|---|---|
| Debtor days | 127 | 138 |
| Inventory days | 128 | 125 |
| Days payable | 36 | 48 |
| Cash conversion cycle | 218 | 214 |
| Working capital days | 129 | 163 |
Anondita Medicare peers and competitors
Listed SME companies in the same industryBy sales, Anondita Medicare is number 1 of the 8 listed SME companies in personal products.
Each company's latest full year and its latest close; companies the exchange puts in the same industry, whose businesses can differ a good deal. A list, not a comparison of their shares.
| Company | Market cap ₹ cr | P/E | Sales ₹ cr | Profit ₹ cr | Op. margin | Debt/equity |
|---|---|---|---|---|---|---|
| Anondita Medicare | 1,978 | 57.7 | 137 | 34.3 | 36.9% | 0.26 |
| H. R. Hygiene Products | 139 | 12.6 | 130 | 11 | 14.0% | 0.51 |
| Recode Studios | 486 | 44.2 | 80 | 11 | 21.0% | 0.30 |
| Medistep Healthcare | 29 | 4.9 | 70.8 | 6 | 11.6% | 0.14 |
| Aakaar Medical Technologies | 101 | 15.1 | 67 | 6.6 | 15.4% | 0.34 |
| Macobs Technologies | 195 | 67.2 | 41.4 | 2.9 | 8.3% | 0.06 |
| Ravelcare | 68 | 13.1 | 27 | 5.2 | 26.2% | 0.00 |
| Novateor Research Laboratories | 23 | 227.0 | 3.8 | 0.1 | -2.6% | 0.09 |
| Median of the 7 others | 101 | 15.1 | 67 | 6 | 14.0% | 0.14 |
Anondita Medicare shareholding pattern
Promoters, FIIs, DIIs, HNIs and small holdersThe promoters own more than half the company, a little less than in the first filing shown. Foreign and Indian funds own a noticeable share. The number of shareholders has grown a lot.
Anondita Medicare shareholding pattern
Per cent of shares, from the patterns filed with the exchange. Tap + to see everyone holding 1% or more in that group. HNIs and small holders show only where the pattern was filed in full.
| Sep 25 | Mar 26 | Sep 26 | |
|---|---|---|---|
| Promoters | 61.79% | 62.40% | 59.26% |
| Foreign investors (FIIs) | 4.24% | 3.40% | 2.48% |
| Indian institutions (DIIs) | 6.55% | 5.70% | 6.05% |
| HNIs (over ₹2 lakh each) | 10.08% | 13.12% | 13.59% |
| Small holders (up to ₹2 lakh) | 7.04% | 5.73% | 8.08% |
| Companies and others | 10.30% | 9.65% | 10.54% |
| Number of shareholders | 621 | 530 | 2,070 |
The named holders are at 24 Sept 2026, beside 31 March 2026, each under the group the pattern files them in.
Anondita Medicare study: the business from its own documents
Read from 15 of the company's own documentsAnondita Medicare so far
From the company's own record
- 1 Sept 2025Listed on NSE Emerge at ₹145
- 24 Sept 2026Promoters at 59.26%
- 24 June 2026Highest close since listing, ₹1,233.15
Anondita Medicare key facts from the filings
Each figure with the document it comes from
- Production capacity
- 869 million pieces
- Condoms the Noida plant can make in a year, up from 562 million after 307 million pieces were added on 23 February 2026.Investor presentation, June 2026, p.11
- Production in FY26
- 432 million pieces
- Condoms made in FY26, against 259 million in FY25.Annual report 2025-26, p.10
- Lines being added
- 4 on trial, 4 being built
- Four lines of about 250 million pieces a year are on trial and four more are being built, due by January 2027, the managing director says.Annual report 2025-26, p.13
- Government share of sales
- About 42%
- Share of FY26 sales made to government buyers; the rest came mostly from the company's own brand, the chief financial officer said.Earnings call transcript, May 2026, p.12
- Government tender
- 80.1 million pieces
- Declared the lowest bidder (L1) in August 2026 in a Central Medical Services Society tender to supply 8,00,62,000 condoms for the family planning programme.Press release, September 2026, p.2
Show 3 more facts
- Retail reach
- 4,569 retailers
- Served through 26 super stockists and 195 distributors across eight states and regions, including Maharashtra, West Bengal and Rajasthan.Investor presentation, June 2026, p.15
- Export certificates
- MDSAP and SABS
- MDSAP certification in November 2025 covers selling in Australia, Brazil, Canada, Japan and the United States; SABS certification covers male condoms for South Africa.Annual report 2025-26, p.13 and p.11
- Credit rating
- BWR BBB/Stable
- Brickwork Ratings rated ₹56.2 cr of bank loans in May 2026, noting the promoter centred management and working capital tied up in long credit periods.Credit rating note, May 2026, p.2
What the company said, and what happened
The company's own statements, attributed, set against what it later reported; not newboard's estimates
The company says it is targeting revenue growth of 60 to 70% by FY27 with an EBITDA margin of about 30%, and an export share of 25% by FY27. On the May 2026 call the managing director said the South African government had approved the company to supply for five years, with the purchase order still pending. A June 2026 press release says the company is targeting ₹1,000 cr of revenue in the next two years. These are the company's statements, not newboard's.
| What management said | When | What happened |
|---|---|---|
| UN qualification under way, with an export launch by the end of the then current year or in the first quarter of the next | Offer document | At the May 2026 call the UN application was still pending; trial export orders had come from Kenya |
Is it a good business? Six questions
Each answer is about that one question, read from the documents; tap one for the evidence. Not a view on the shares.
Anondita Medicare makes condoms in Noida and earns its money from its own Cobra brand and from government family planning orders, and the company says the brand earns better margins.
Its weak spot is slow payment from government buyers and heavy spending on new lines, so cash from the business has trailed profit.
WatchCan it set its own prices?Much of the business is won on price. Government orders go to the lowest bidder, and the offer document says price decides most customer choices.
AverageHow strong is it against rivals?It makes and packs its own products and is strong in North India, but it is small next to national brands.
WatchWho are its customers?Government buyers are the largest single group, alongside shops reached through its own subsidiary and distributors.
WatchDoes it need a lot of money?Yes. New lines cost a lot, and slow government payments tie up money in receivables.
AverageCan it keep finding new work?It keeps winning government tenders at home and has new certificates for selling abroad, but the big export orders were not yet confirmed at the last call.
AverageDo good and bad years swing a lot?Sales have grown each year so far, but they bunch up at the year end and latex costs move with the seasons.
Who runs Anondita Medicare?
Promoters, directors and officers; tap a name for the background
AGAnupam GhoshPromoter and Managing Director · holds 61.99%
Has 25 years of experience in the healthcare products industry. Started in 1999 packing and selling contraceptives and gloves through the proprietorship M/s Healthcare Products, set up a condom plant in 2004, renamed the firm M/s Anondita Healthcare in 2013, and the company took over that business in 2024. Education: Senior Secondary (10+2).
Offer document, p.163 and p.210SGSonia GhoshPromoter (Whole Time Director until 29 October 2025)
B.A. (Hons.) in Philosophy from Indraprastha College, New Delhi. Has 10 years of experience in administration and human resources and has been a director since 2014 at the group company Anondita Healthcare Products Private Limited. The offer document lists Sonia Ghosh as the wife of Anupam Ghosh and the mother of Reshant Ghosh. Resigned as Whole Time Director on 29 October 2025 (Annual report 2025-26, p.36).
Offer document, p.163, p.211 and p.215RGReshant GhoshPromoter and Whole Time Director
Founder and Director of the subsidiary Anondita Healthcare and Rubber Products India Limited, with about three years of experience in marketing: market analysis, marketing strategy and building a network of distributors and retailers. Education: Senior Secondary (10+2).
Annual report 2025-26, p.16; Offer document, p.211LSLakhinder SinghNon-Executive Director
Retired Government of India officer with over 36 years in taxation and revenue administration; served as Joint Secretary, Department of Revenue, Director General (Safeguards), Ministry of Finance, and Chief Commissioner, Customs and Central Excise, Meerut, with additional charge of Lucknow. M.A. in English Literature, B.I.T.S. Pilani.
Annual report 2025-26, p.17; Offer document, p.214NGNishi GoelIndependent Director
Chartered Accountant and proprietor of M/s Nishi Goel & Associates, with experience in corporate law, direct and indirect taxation, auditing and accounting. Began in 2007 in the IT sector reviewing financial software and later worked at ICAI on putting XBRL in place in India.
Annual report 2025-26, p.16; Offer document, p.214GKGaurav KumarIndependent Director
Qualified Company Secretary (ICSI) with over eight years of experience and proprietor of M/s K Gaurav & Co., consulting on corporate law and compliance in the real estate and NBFC sectors. Chairs the audit committee and the nomination and remuneration committee.
Annual report 2025-26, p.17Anondita Medicare latest news and announcements
Announcements · Documents · Corporate actionsWhat changed recently
Each half-year is set against the same half a year earlier
- H2 FY26: sales ₹83.3 cr (+81%), net profit ₹21.3 cr (+113%) on H2 FY25.
- Shareholding, 24 Sept 2026: promoters 62.40% to 59.26%.
Anondita Medicare announcements
153 on record, latest first; each opens the filing on the exchange
- Quarterly Compliance Report on Corporate governance - within 21 days from the enSubmission of Certificate in relation to Non- Applicability of Compliance Report on the Corporate Governance under Regulation 27 (2) of the SEBI (Listing ObligaPDF ↗
- Certificate under SEBI (Depositories and Participants) Regulations, 2018Certificate under SEBI (Depositories and Participants) Regulations, 2018PDF ↗
- Shareholders meetingSrutinizers report of Annual General Meeting held on September 29, 2026. Further, the company has informed the Exchange regarding voting resultsPDF ↗
- Shareholders meetingProceedings of Annual General Meeting held on September 29, 2026PDF ↗
- Copy of Newspaper PublicationRegarding Basis of Allotment of Right IssuePDF ↗
- Trading WindowClosure pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015PDF ↗
- Allotment of Securitiesallotment of 958166 fully paid up equity shares pursuant to Rights Issue at its meeting held on September 24, 2026PDF ↗
- Outcome of Board MeetingHeld on September 24, 2026PDF ↗
- Updates'Withdrawal of Nullification Letter and confirmation of allotment of 9,58,166 Rights Equity Shares as per the Corrigendum to the Letter of Offer dated SeptemberPDF ↗
- Record Datethat the Record Date is September 22, 2026 and the Book Closure period for the purpose of the 3rd Annual General Meeting (AGM) for the financial year 2025 26 wiPDF ↗
- Copy of Newspaper PublicationRelating to arrangements for disposal of odd lots in respect of Right IssuePDF ↗
- Updates'INTIMATION REGARDING PARTIAL NULLIFICATION OF CORRIGENDUM TO THE LETTER OF OFFER DATED AUGUST 27, 2026'PDF ↗
Anondita Medicare annual reports, earnings calls and documents
Every document links to its source; “read” marks those this page is built from
- Offer document ↗read
- 2 June 2026 ↗read
- 31 May 2026 ↗read
- 28 May 2026 ↗read
- 30 June 2026 ↗read
- 31 May 2026 ↗read
- 31 March 2026 ↗read
Anondita Medicare share split, bonus and dividends
From the corporate actions the company announces on the exchange
- Rights issueRIGHTS 97:1831 @ PREMIUM RS 940/-ex-date 2 Sept 2026
Checks we ran on Anondita Medicare's data · 9
Before any number shows, it goes through the same checks. A figure that fails is held back, never shown as if it were right.
- ✓Balance sheet totals add up for FY25 and FY26.
- ✓Market cap uses the share count in the latest shareholding pattern (1,90,44,784 shares).
- !The FY26 results imply 1,80,90,000 shares at face value ₹10, which disagrees with the shareholding pattern; the pattern is used.
- ✓Promoter pledge figures are within possible limits in every shareholding pattern shown.
- ✓Promoter and public holdings add up to 100% in every shareholding pattern shown.
- ✓The two half-years of FY26 add up to the full-year sales.
- ✓Earnings per share moves in line with profit across the years shown.
- ✓Revenue and profit are reported for every year shown, FY25 to FY26.
- iPrices run to the close on 14 Oct 2026, from the exchange's daily figures.
Questions people ask about Anondita Medicare
What does Anondita Medicare do?
Anondita Medicare makes condoms at its own plant in Noida and sells them under its own brand, Cobra, to shops in several states and to government health programmes. Its shares trade on NSE Emerge.
What is the share price of Anondita Medicare?
₹1,038 at the close on 19 Nov 2026, from the exchange's daily figures.
What is the market cap of Anondita Medicare?
₹1,978 cr at the close on 19 Nov 2026, on 1,90,44,784 shares.
What is the P/E of Anondita Medicare?
57.7 times FY26 profit at the close on 19 Nov 2026 (our arithmetic).
What are Anondita Medicare's revenue and profit?
Revenue ₹137 cr and profit after tax ₹34 cr in FY26.
Who are the promoters of Anondita Medicare?
Anupam Ghosh, Sonia Ghosh, Reshant Ghosh; promoters held 59.26% at 24 Sept 2026.
What was the IPO price of Anondita Medicare?
₹145 a share; it listed on 1 Sept 2025.
What is Anondita Medicare's website?
www.anonditamedicare.com
More SME companies like Anondita Medicare
Other listed SME companies in personal products, the closest in size first, each read from its own documents.
- Recode StudiosRECODE · BSE SME · Personal ProductsMarket cap ₹373 cr
- Macobs TechnologiesMACOBSTECH · NSE Emerge · Personal Products · listed 2024Market cap ₹186 cr
- H. R. Hygiene ProductsHRHYGIENE · BSE SME · Personal ProductsMarket cap ₹150 cr
- Aakaar Medical TechnologiesAAKAAR · NSE Emerge · Personal Products · listed 2025Market cap ₹94 cr
- RavelcareRAVEL · BSE SME · Personal ProductsMarket cap ₹64 cr
- Medistep HealthcareMEDISTEP · NSE Emerge · Personal Products · listed 2025Market cap ₹27 cr
Every listed SME company in Personal Products → · SME companies listed in 2025 →
Built from 3 earnings call transcripts, 3 investor presentations, 3 press releases, 2 annual reports, 2 credit rating notes, 1 offer document, 1 result filing, 153 exchange announcements, 3 shareholding patterns and 2 years of reported results. Every figure carries its source; where the documents are silent, the page says so.